PRTAHealthcare · BiotechnologyThe 7 Wall Street analysts covering Prothena Corp. Plc hold a median 12-month price target of $20 — +136.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Prothena Corp. Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (100): Sales and profits are climbing, and climbing faster than before.
Accruals (45): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PRTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +136.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 May 2026 | Citizens | Maintains | Market Outperform | $19 → $20 |
| 20 Feb 2026 | RBC Capital | Maintains | Sector Perform | — |
| 1 Dec 2025 | Citizens | Maintains | Market Outperform | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 28 Oct 2025 | Piper Sandler | Maintains | Overweight | — |
| 7 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Sept 2025 | JMP Securities | Maintains | Market Outperform | — |
| 28 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 28 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 5 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 5 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Aug 2025 | RBC Capital | Maintains | Sector Perform | — |
| 20 June 2025 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 28 May 2025 | B of A Securities | Downgrade | Underperform | — |
| 27 May 2025 | Chardan Capital | Maintains | Buy | — |
| 27 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 27 May 2025 | Oppenheimer | Downgrade | Perform | — |
| 27 May 2025 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PRTA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Prothena Corp. Plc returned −19.2% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 16% of US stocks
Cheaper than 52% of US stocks
Cheaper than 76% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 4% of US stocks
Higher than 7% of US stocks
Higher than 34% of US stocks
Higher than 26% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Prothena Corp. Plc has a market value of $434.8M and an enterprise value of $153.6M.
Revenue in the twelve months to 30 June 2026: $54.5M. The latest quarter shrank 77.1% year on year.
Net income over the same four quarters: −$44.0M, a −80.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.84.
Free cash flow in the twelve months to 30 June 2026: −$60.7M.
Prothena Corp. Plc spent $22.5M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −1.9×; forward P/E: −6.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.36%, paying out 0% of earnings.
Prothena Corp. Plc employs 67 people — $814K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Prothena Corp. Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Prothena announced it will report its third-quarter 2026 financial results on November 5.
Why it matters — PRTA watchers can note the scheduled date for the company’s quarterly financial update.
Prothena's pharmaceutical partnerships offer $3 billion in potential milestone payments plus royalties. Clinical risks and partners' control remain challenges.
Why it matters — PRTA watchers may weigh the potential partnership proceeds and royalties against clinical risk and the partners' control.
Zacks Investment Research compares CorMedix (CRMD) and Prothena (PRTA) for investors interested in value among Medical - Biomedical and Genetics stocks. The excerpt poses which stock offers better value but gives no conclusion.
Why it matters — The item directly compares PRTA with CRMD from a value-investing perspective, though the excerpt does not indicate which stock is favored.
Zacks Investment Research highlighted four biotechnology stocks advancing Alzheimer's disease therapies, ranging from marketed treatments to experimental programs targeting amyloid and tau proteins, in a piece timed to World Alzheimer's Day.
Why it matters — Prothena, which focuses on Alzheimer's and neurodegenerative disease research, is one of the biotechnology companies operating in this space, so the coverage draws attention to the broader competitive landscape it participates in.
Prothena Corporation plc announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company made the announcement via Business Wire from its Dublin, Ireland headquarters.
Why it matters — A PRTA watcher would care because conference participation gives the company a public platform to present its business to investors and industry participants.
The 7 Wall Street analysts covering Prothena Corp. Plc have a median 12-month price target of $20, with estimates ranging from $8 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Prothena Corp. Plc, 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Prothena Corp. Plc 98 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Prothena Corp. Plc ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +136.1% from the last close, and Ticker Nerd's factor model ranks Prothena Corp. Plc 98 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Prothena Corp. Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $36 over the next 12 months.
Prothena Corp. Plc returned -19.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Prothena Corp PLC is a clinical-stage biotechnology company focused on discovering and developing therapies for diseases linked to protein dysregulation. The company’s current work centers on investigational treatments for neurodegenerative disorders and rare peripheral amyloid diseases, areas where misfolded proteins play a critical role in disease progression.
The most recent item we track (Business Wire, 29 Oct 2026): "Prothena to Report Third Quarter 2026 Financial Results on November 5". Prothena announced it will report its third-quarter 2026 financial results on November 5.
Prothena Corp PLC is a clinical-stage biotechnology company focused on discovering and developing therapies for diseases linked to protein dysregulation. The company’s current work centers on investigational treatments for neurodegenerative disorders and rare peripheral amyloid diseases, areas where misfolded proteins play a critical role in disease progression. Its pipeline includes both wholly owned and partnered programs aimed at conditions such as Alzheimer’s disease, Parkinson’s disease, AL amyloidosis, and ATTR amyloidosis. Prothena Corp PLC also applies its proprietary scientific platform to investigate targeted biologic therapies designed to address complex disease pathways in the brain and peripheral tissues. Headquartered in Dublin, Ireland, Prothena Corp PLC plays a specialized role in the biotechnology market by advancing experimental medicines for serious disorders with limited treatment options.
CEO Dr. Gene G. Kinney Ph.D. · 67 employees · Ireland · https://www.prothena.com
